Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised $315 million by offering 17.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to raise $200 million, before it increased the proposed share offering on Wednesday ($250mm), and upsized again at pricing. The offering raised 58% more proceeds than originally anticipated
Bicara Therapeutics' lead candidate, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma (HNSCC). The company is conducting an ongoing Phase 1/1b trial in the US in combination with pembrolizumab. It plans to initiate a pivotal Phase 2/3 trial late in the 4Q24 or early in the 1Q25.
The Boston, MA-based company plans to list on the Nasdaq under the symbol BCAX. Morgan Stanley, TD Cowen, Cantor Fitzgerald, and Stifel acted as joint bookrunners on the deal.
Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range
September 13, 2024

